Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Aug 30, 2022 5:02pm
262 Views
Post# 34930792

Fatty heart

Fatty heart

 

This study started while ago and the status was unknown, it was recently updated as complete so I guess there were some Covid related issues for the long delay. The purpose was to evaluate the relationship between GH deficiency and fat accumulation inside the heart muscles. Obviously obesity/high levels of VAT will be causing cardiac steatosis but HIV and long term use of antivirals also disturbs glucose/fat metabolism resulting in high blood sugar/fat. That’s the thinking among others behind increased prevalence of fatty liver/heart among PLWH. So it will be interesting to know what was the conclusion. Again point is there are several ongoing studies evaluating various therapeutic benefits of Tesamorelin and some are for serious conditions such as heart attack although

ischaemic heart diseases are more common metabolic heart diseases are still very common specifically among PLWH.

 

Growth Hormone Dynamics and Cardiac Steatosis in HIV - Full Text View - ClinicalTrials.gov

<< Previous
Bullboard Posts
Next >>